Transcatheter aortic valve replacement (TAVR) has emerged as the preferred treatment for aortic stenosis. However, there is a lack of long-term outcome data for low-risk patients. The 5-year results from the Evolut Low-Risk randomized trial address this gap, offering compelling evidence with no significant negative signals regarding TAVR's clinical outcomes and valve performance. 

In this episode, Drs. Richard A. Chazal and Michael J. Reardon delve into the 5-year results from the Evolut Low-Risk randomized trial, offering valuable insights about the future of TAVR and its impact on patient care. 

Related References: 

1. Popma JJ, Deeb GM, Yakubov SJ, et al; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16. PMID: 30883053. 

Subscribe on Apple Podcasts| Subscribe to ACCEL